The German company BioNTech said that they could not report on the start of vaccination against COVID in Germany. It depends on the regulator’s decision.
“We do not name the terms because we do not affect the work of the regulator; we can only apply,” the company’s press service told.
Mainz-based bioengineering company BioNTech and US pharmaceutical giant Pfizer have previously reported a successful phase three clinical trial of the COVID vaccine. With the vaccine expected to be registered in the US in November, the company said in a statement. The request will be sent to the US food and drug administration (FDA) next week.
According to the release, the third phase of the BNT162b2 vaccine’s clinical trials showed its effectiveness by more than 90% among subjects.